There are many monoclonal antibodies for which the hybridoma cell line is unavailable. To complement our hybridoma sequencing service, we are also offering a de novo antibody protein sequencing service.
By combining mass spectrometry with high accuracy de novo peptide sequencing and assembly of overlapping peptides, the amino acid sequences of the variable domains are determined.
We guarantee to deliver a functional antibody sequence along with a comprehensive sequencing report with full sequence coverage. In combination with our transient expression service, we can sequence an antibody and deliver recombinant versions in as little as 9 weeks.

De novo sequencing workflow: The antibody is digested using multiple enzymes. On each digest LC-MS-MS is performed and peptides predicted de novo. Using proprietary software, overlapping peptides are assembled into a full coverage protein sequence.
For more information please contact us.
Customer Provides | Mass Spectrometric Sequencing | Antibody Expression | Timeline | Deliverables |
---|---|---|---|---|
Monoclonal antibody, >0.1 mg, 95% pure |
|
|
9 weeks |
|